20323-74-4

Basic information

• Product Name: ETHYL 2-AMINO-4,5-DIMETHOXYBENZOATE
• Synonyms: 6-AMINO-3,4-DIMETHOXYBENZOIC ACID ETHYL ESTER;ETHYL 6-AMINO-3,4-DIMETHOXYBENZOATE;ETHYL 2-AMINO-4,5-DIMETHOXYBENZOATE;Benzoic acid, 2-amino-4,5-dimethoxy-, ethyl ester;2-Amino-4,5-dimethoxybenzoic acid ethyl ester;ethyl 4,5-dimethoxyanthranilate;Einecs 243-732-8
• CAS NO: 20323-74-4
• Molecular Formula: C₁₁H₁₅NO₄
• Molecular Weight: 225.24
• EINECS: 243-732-8
• Product Categories: Aromatic Esters
• Mol File: 20323-74-4.mol
• Article Data: 14

Chemical Properties

• Melting Point: 86-88°C
• Boiling Point: 355.9 °C at 760 mmHg
• Flash Point: 164 °C
• Appearance: /
• Density: 1.16 g/cm³
• Vapor Pressure: 3.02E-05mmHg at 25°C
• Refractive Index: 1.533
• Storage Temp.: under inert gas (nitrogen or Argon) at 2–8 °C
• PKA: 2.69±0.10(Predicted)
• BRN: 2646663
• CAS DataBase Reference: ETHYL 2-AMINO-4,5-DIMETHOXYBENZOATE(CAS DataBase Reference)
• NIST Chemistry Reference: ETHYL 2-AMINO-4,5-DIMETHOXYBENZOATE(20323-74-4)
• EPA Substance Registry System: ETHYL 2-AMINO-4,5-DIMETHOXYBENZOATE(20323-74-4)

Safety Data

• Safety Statements: 22-24/25
• Hazardous Substances Data: 20323-74-4(Hazardous Substances Data)

Usage

Chemical Properties

Off-white crystalline powder

InChI:InChI=1/C11H15NO4/c1-4-16-11(13)7-5-9(14-2)10(15-3)6-8(7)12/h5-6H,4,12H2,1-3H3

Upstream product

• 103580-03-6 Ethyl 2,3-dimethoxy-6-nitrobenzoate 
• 64-17-5 ethanol 
• 5653-40-7 2-Amino-4,5-dimethoxybenzoic acid 
• 93-07-2 Veratric acid 
• 3943-77-9 ethyl veratrate 
• 4998-07-6 4,5-dimethoxy-2-nitro-benzoic acid 
• 100905-33-7 ethyl 2-nitro-4,5-dimethoxybenzoate 

Downstream Products

• 905306-05-0 4-[(3-acetylenephenyl)amino]-7-methoxyquinazolin-6-ol 
• 905306-07-2 4-[(3-acetylenephenyl)amino]-7-methoxyquinazolin-6-yl acetate 
• 295330-64-2 4-[(3-bromo-phenyl)amino]-6-methylcarbonyloxy-7-methoxy-quinazoline 
• 1389355-33-2 N-(3-bromophenyl)-6-(2-[18F]fluoroethoxy)-7-methoxyquinazolin-4-amine 
• 179688-53-0 6-acetoxy-7-methoxy-3,4-dihydroquinazolin-4-one 
• 230955-75-6 6-acetoxy-4-chloro-7-methoxyquinazoline 
• 295330-61-9 4-[(3-bromophenyl)amino]-6-hydroxy-7-methoxyquinazoline 
• 179688-52-9 6-hydroxy-7-methoxyquinazolin-4(3H)-one 
• 184475-71-6 4-(3-chloro-4-fluorophenylamino)-6-hydroxy-7-methoxyquinazoline 
• 788136-89-0 4-((3-chloro-4-fluorophenyl)amino)-7-methoxyquinazolin-6-yl acetate 
• 13794-72-4 3H-6,7-dimethoxyquinazolin-4-one 
• 334025-76-2 4,5-dimethoxy-2-(4-nitro-benzoylamino)-benzoic acid ethyl ester 

Relevant articles and documents

Overcoming the Deallylation Problem: Palladium(II)-Catalyzed Chemo-, Regio-, and Stereoselective Allylic Oxidation of Aryl Allyl Ether, Amine, and Amino Acids

We report herein a Pd(II)/bis-sulfoxide-catalyzed intramolecular allylic C-H acetoxylation of aryl allyl ether, amine, and amino acids with the retention of a labile allyl moiety. Mechanistically, the reaction proceeds through a distinct double-bond isomerization from the allylic to the vinylic position followed by intramolecular carboxypalladation and the β-hydride elimination pathway. For the first time, C-H oxidation of N-allyl-protected amino acids to furnish five-membered heterocycles through 1,3-syn-addition is established with excellent diastereoselectivity.

Facile Synthesis of Novel Perfluorocarbon-Modulated 4-Anilinoquinazoline Analogues

4-Anilinoquinazoline analogues stand out among many kinds of small molecules that inhibit the tyrosine kinase activities of epidermal growth factor receptor (EGFR), thus serving as significant molecular targets for anticancer drug design. Herein, a series of novel perfluorocarbon (PFC) modulated 4-anilinoquinazolines were designed and prepared straightforwardly by nucleophilic substitution reaction of various anilinoquinazolines and PFC-derived methanesulfonate. In the presence of base, the reaction proceeded smoothly to afford a wide range of 4-anilinoquinazolines with different substituents on aniline moiety in good to high yields. Furthermore, the PFC-modified analogues of gefitinib and erlotinib were also obtained in 93% and 90% respectively, which may have potential for developing new inhibitors of the epidermal growth factor receptor (EGFR) tyrosine kinase and fluorinated contrast agents (CA) for 19F MRI.

Model 18 F mark substituted [...] compound and its preparation method and tumor PET imaging applications

The invention provides a novel F marked substituted quinazoline compound. The novel F marked substituted quinazoline compound is characterized in that one end of the novel F marked substituted quinazoline compound has a F substituted alkyloxy structure; the other end of the compound has a 6,7-substituted quinazoline structure, and a substituent R1 is positioned in the 4 position of a quinazoline maternal, and is a 2-, 3-, 4-F substituted alkyloxy group; and a substituent R2 is positioned in the 6 position of the quinazoline maternal, and is a methoxyethoxy group, a methoxy group, or a morpholinepropanolato group. The structural formula of the compound is shown as A in the specification. Results of experiments show that the compound has the advantages of good bioactivity, good serum stability, low intake in tissues of the liver and the like, and high enrichment and slow removal rate in tumors, and the marking precursor of the compound has the advantages of easy synthesis, extremely high marking rate and the like, so the compound has a huge potential for the tumor PET development.